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BACKGROUND: Recent advances in the study and clinical
applications of circulating tumor DNA (ctDNA) are
limited by practical considerations of sample collection.
Whole-genome sequencing (WGS) is increasingly used
for analysis of ctDNA, identifying copy-number altera-
tions and fragmentation patterns. We hypothesized that
low-depth/shallow WGS (sWGS) data may be gener-
ated from minute amounts of cell-free DNA, and that
fragment-size selection may remove contaminating ge-
nomic DNA from small blood volumes. Dried blood
spots have practical advantages for sample collection,
may facilitate serial sampling, and could support novel
study designs in humans and animal models.
METHODS: We developed a protocol for the isolation and
analysis of cell-free DNA from dried blood spots using fil-
ter paper cards and bead-based size selection. DNA
extracted and size-selected from dried spots was analyzed
using sWGS and polymerase chain reaction (PCR).
RESULTS: Analyzing a 50 lL dried blood spot from
frozen whole blood of a patient with melanoma, we
identified ctDNA based on the presence of tumor-
specific somatic copy-number alterations, and found a
fragment-size profile similar to that observed in plasma
DNA. We found alterations in different chromosomes
in blood spots from 2 patients with high-grade serous
ovarian carcinoma. Extending this approach to serial
dried blood spots from mouse xenograft models, we de-
tect tumor-derived cell-free DNA and identified ctDNA
from the originally grafted ascites.
CONCLUSION: Our data suggest that ctDNA can be
detected and monitored in dried blood spots from
archived and fresh blood samples, enabling new
approaches for sample collection and novel study/trial
designs for both patients and in vivo models.
Introduction
Circulating tumor DNA (ctDNA) can be used to sensi-
tively detect and quantify disease burden using a variety
of sequencing-based approaches (1). For example, using
shallow whole-genome sequencing (sWGS), ctDNA can
be detected down to mutant allele fractions of 3%
through analysis of somatic copy-number alterations
(SCNAs) (2, 3). Alternatively, leveraging differences in
fragment size between tumor-derived and non-tumor
cell-free DNA molecules (cfDNA) can enhance the de-
tection of genomic alterations and the identification of
plasma samples from patients with cancer compared to
healthy individuals (4, 5). Although sWGS generates
data on only a fraction of a single genome (0.3 genome
equivalents correspond to 1 pg DNA), sequencing
libraries for sWGS have traditionally been generated
from larger amounts of cfDNA extracted from milliliter
volumes of plasma from a venous blood sample (3).
Established protocols for collection of plasma for
ctDNA analysis require venipuncture, and prompt spin-
ning of EDTA-containing tubes or delayed spinning of
tubes containing cell preservatives/fixatives (6). These
restrict the possible study designs, requiring samples to
be collected by trained staff and limiting the frequency
at which serial samples can be collected.
The use of limited blood volumes and dried blood
spots for analysis of cfDNA may facilitate new trial designs,
widen clinical applications, and enable point-of-care testing
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and self-collection of samples. Additionally, analysis of
minute amounts of blood may facilitate longitudinal
ctDNA monitoring from animal models with limited
circulating blood volume. In prenatal diagnostics, poly-
merase chain reaction (PCR) has been used to carry out
fetal Rh blood group D antigen (RHD) genotyping and
HIV detection using maternal dried blood spots (7, 8).
In applications to cancer, ctDNA from a limited plasma
volume was previously analyzed in a study of a mouse
xenograft model, where quantitative PCR was used to
measure the human long interspersed nuclear element-1
(hLINE-1) as a measure of tumor burden (9). In another
pilot study in patients with breast cancer, whole-genome
amplification was performed on blood obtained from a
finger prick (10). The study found comparable allelic
fractions of somatic mutations between the finger prick
sample and matched venous blood (10). Sensitive detec-
tion of ctDNA from limited volumes or blood spots rep-
resents a technical challenge due to the limited total
number of mutant molecules. Whole blood samples are
considered inferior to carefully collected plasma samples
due to the presence of contaminating genomic DNA
(gDNA) from lysed white cells (1, 11), which signifi-
cantly dilutes tumor-derived ctDNA signal. In this
study, we present methods for cfDNA extraction from
dried blood spots and the subsequent analysis and detec-
tion of ctDNA.
Methods
CELL-FREE DNA EXTRACTION FROM DRIED BLOOD SPOTS
The dried blood-spot data in Fig. 1 were generated
from a baseline sample from a patient with Stage IV
melanoma recruited to the MelResist study (REC 11/
NE/0312). MelResist is a translational study of response
and resistance mechanisms to systemic therapies of mel-
anoma, including B-Raf proto-oncogene, serine/threo-
nine kinase (BRAF) -targeted therapy and
immunotherapy. The sample was taken prior to the ini-
tiation of anti-BRAF targeted therapy and the subse-
quent clinical timecourse is shown in Wan et al. (12), as
patient 65. Whole blood samples were collected into 9-
mL K2-EDTA tubes. The corresponding plasma sample
was derived from a separate K2-EDTA blood tube taken
at the same time which underwent double centrifuga-
tion at 1600g for 10 mins, followed by 18 800g for 10
mins in a benchtop microfuge at room temperature.
Samples were retrieved after storing at 80C for 5
years before starting the analysis. Upon thawing, 50 lL
of the whole blood were transferred to Whatman
FTATM Classic Cards (Merck) and allowed to air dry
for 15 minutes before DNA extraction. For longitudinal
xenograft sampling (Fig. 2, C), blood spots were
obtained from a tail vein nick, collected with a capillary
and spotted onto the Whatman FTA Classic Card.
Blood spots obtained from 2 healthy volunteers (ana-
lyzed in dPCR experiments) and 2 patients with ovarian
cancer (analyzed in sWGS experiments) were derived
within 1 hour from blood collected in K2-EDTA tubes,
applied to Whatman FTA Classic Cards and stored at
room temperature. DNA was extracted from the card
using the QIAamp DNA Investigator kit (Qiagen), fol-
lowing the manufacturer’s recommended extraction pro-
tocol for FTA and Guthrie cards with the following
modifications: three 3 mm punches were made from the
blood spot, carrier RNA was added to Buffer AL as per
the manufacturer’s recommendation, and 2 rounds of
elution using 25 lL of elution buffer were used.
SIZE SELECTION AND LIBRARY PREPARATION OF
BLOOD-SPOT CELL-FREE DNA
We opted to perform size selection to remove contami-
nating long gDNA fragments that would have prohib-
ited library preparation. Thus, a right-side size selection
was performed on DNA eluates using AMPure XP
beads (Beckman Coulter). For this purpose, we adapted
a protocol for a right-side size selection (13). Following
optimization of bead:sample ratios for cfDNA fragment
sizes, we used a bead:sample ratio of 1:1 to remove
contaminating gDNA. The supernatant was retained as
part of the right-side size-selection protocol. A second
size-selection step used a 7:1 bead:sample ratio to cap-
ture remaining fragments, and the size-selected DNA
was eluted in 25 lL water. Blood-spot eluates were
concentrated using a vacuum concentrator (SpeedVac)
to 10 lL volume, which is the maximum recommended
volume for downstream library preparation using the
ThruPLEX Tag-seq kit (Takara). Sixteen cycles of
library amplification were used. Libraries underwent
QC using Bioanalyzer 2100 (Agilent) and quantitative
PCR (qPCR) with the Illumina/ROX low Library
Quantification kit (Roche) on a QuantStudio 6 (Life
Technologies). Libraries were submitted for sWGS on a
HiSeq4000 (Illumina, paired-end 150 bp).
PLASMA LIBRARY PREPARATION
A plasma cfDNA library was prepared for the matched
timepoint where the blood spot was collected. The
plasma was obtained as described above. The DNA was
extracted using the QIAsymphony (Qiagen) with the
DSP Circulating DNA Kit and quantified by digital
PCR on a BioMark HD (Fluidigm) using a 65 bp
TaqMan assay for the housekeeping gene ribonuclease
P/MRP subunit p30 (RPP30) (Sigma Aldrich) (14) and
55 cycles of amplification (15). Using the estimated
number of RPP30 DNA copies per lL of eluate, the
cfDNA concentration in the original sample was esti-
mated and 10 ng were used for the library preparation.
The ThruPLEX Tag-seq kit (Takara) was used accord-
ing to the manufacturer’s instructions and 7 cycles of
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Fig. 1. Detection of ctDNA in a dried blood spot from a cancer patient. A) Overview of the analysis of dried blood spots: DNA ex-
traction, followed by size selection, and low-depth WGS. B) Bioanalyzer trace of DNA extracted from a 50mL dried blood spot
from blood of a patient with advanced melanoma, showing a high level of genomic DNA contamination (>1 kbp) and no clear
cfDNA peak (166 bp). C) Copy-number profiles from sWGS of a sequencing library generated from the same dried blood spot
as in (B) after size selection, from a matched plasma sample from the same individual and timepoint and the matched tumor tis-
sue. Segments colored in blue, red, and green indicate regions of copy-number neutrality, gain, and loss, respectively. D)
Correlation of log2 ratios for each copy-number bin using ichorCNA (2), comparing bins between matched blood spot and plasma
data. The correlation in log2 ratios for all bins between the two samples was 0.97 (Pearson r, P< 2.2  1016). E) Size profile of
the sequencing reads generated from the size selected blood spot DNA library (data shown in panel C). The overall size profile is
comparable to that of cfDNA; i.e., with a peak at 170 bp. F) Length of the sequencing reads (data from panel E) carrying known
patient-specific mutations (light blue), and reads carrying reference alleles at the same loci (dark blue).
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amplification were carried out. After barcoding and sam-
ple amplification, the library underwent bead clean-up
using recommended conditions, followed by qPCR QC
as described in the Size Selection section. The sample
was submitted for sequencing on a HiSeq4000 (paired-
end 150 bp).
TUMOR LIBRARY PREPARATION
For the blood spot from the patient with melanoma, a
tumor sample was collected 6 days after the time-
matched plasma and blood spot sample. Tumor DNA
was extracted as described by Varela et al. (16) and
sheared to 200 bp fragment length using the Covaris
LE220 Focused-ultrasonicator according to the manu-
facturer’s instructions. Fifty nanograms of material were
prepared for sWGS using the ThruPLEX Plasma-seq kit
(Takara) with 7 cycles of amplification. Bead clean-up
and QC were performed as described above. The sample
was submitted for WGS on a HiSeq4000 (paired-end
150 bp). Whole exome sequencing and mutation calling
were performed as described previously (16). A total of
5073 mutations were identified and used for the analysis
of cfDNA and ctDNA fragment length (12).
For the xenograft, material from the engrafted
tumor as well as the human ascites sample used for
grafting were available for analysis. The samples were
extracted using the Qiagen Allprep kit (Qiagen) and
the DNA was sheared to 200 bp fragments as described
above. Fifty nanograms of DNA were prepared with
the ThruPLEX DNA-seq kit (Takara) according to the
manufacturer’s instructions and followed by the recom-
mended bead clean-up. The samples were quantified us-
ing TapeStation (Agilent) and submitted for sequencing
on a HiSeq4000 (single-end 50 bp).
SEQUENCING DATA ANALYSIS
FASTQ files were aligned to the UCSC hg19 genome
using BWA-mem v.0.7.13 with a seed length of 19,
then deduplicated with MarkDuplicates. For sWGS
detection of ctDNA, samples were collapsed using
CONNOR (17) and a family size setting of 1 to opti-
mize the number of included families and the amount
Fig. 2. Copy-number profiles from fresh human dried blood spots. A) Copy-number profile from a fresh blood spot of a Stage
IIIC ovarian cancer patient with progressive disease. B) Copy-number profile from a fresh blood spot of a Stage IV ovarian cancer
patient with stable disease. Segments colored in blue, red, and green indicate regions of copy-number neutrality, gain,
and loss, respectively.
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of data retained (Supplemental Fig. 1, D). ichorCNA
was run on all samples as described previously (2).
For xenograft sequencing analyses, BAM files
underwent alignment to the mouse and human
genomes in parallel using Xenomapper (18). Fragment
lengths were determined for both resulting files using
Picard CollectInsertSizeMetrics (19). Additionally,
ichorCNA (2) was run on the subset of reads aligning to
the human genome to confirm the presence of SCNAs.
To visualize the size profile of mutant reads based on a
list of patient-specific mutations, we followed previously
published methods (5, 12).
LIBRARY DIVERSITY ESTIMATION
To estimate the total number of cfDNA genome copies
present in a blood-spot library, we used CONNOR
(17) to perform deduplication of the blood-spot se-
quencing library based on endogenous barcodes (20)
with minimum family sizes ranging between 1 and 5.
For each family size setting, the mean deduplicated cov-
erage was calculated using Samtools mPileup.
Deduplicated coverage values for each setting were used
as input for diversity estimation using a statistical
method, SPECIES (21). A minimum family size of 1
was used for the data analysis.
DIGITAL PCR OF DRIED BLOOD SPOTS
Selected blood-spot samples were analyzed using
hLINE-1 (9) or RPP30-based (14) digital PCR (dPCR)
assays. RPP30 primers were used with a sequence-
specific TaqMan probe while hLINE-1 primers were
used with EvaGreen on a 12.765 or 48.770 Digital
Array Chip and run on the BioMark HD (Fluidigm).
The (genome copies) count obtained by dPCR were
corrected to account for the dead volume of the chip
and reported as a concentration of the total sample vol-
ume of 50 lL.
Results
We sought to assess the number of cfDNA genome cop-
ies that can be sequenced from a single blood drop or
dried blood spot. Based on previous reports, the median
concentration of cfDNA is approximately 1600 amplifi-
able copies per mL of blood for patients with advanced
cancer (22, 23). This translates to approximately 80
copies of the genome as cfDNA in a blood drop/spot of
50 lL. Assuming a yield in the range of 60–80% in
DNA extraction and efficiency of 15–40% in generat-
ing a sequencing library, this is estimated to result in ap-
proximately 7–25 representation of the genome in
sequencing libraries prepared from cfDNA from a single
blood drop. We therefore hypothesized that low-depth
WGS of cfDNA can be attainable from a dried blood
spot after removal of genomic DNA.
To test this hypothesis, we thawed frozen whole
blood from a patient with Stage IV melanoma, and
transferred 50 lL to a Whatman FTA filter paper card.
After drying the card for 15 minutes, we performed
DNA extraction and library preparation from the dried
blood spot (Fig. 1, A). Quality control using capillary
electrophoresis revealed contaminating gDNA, as indi-
cated by an excess of large DNA fragments for blood
spots prepared from frozen whole blood (Fig. 1, B). In
order to assess the effect of a freeze-thaw cycle on the
fragment-size profile from a dried blood spot, we
obtained the size profile of a blood spot generated from
fresh whole blood from a healthy volunteer prior to size
selection (Supplemental Fig. 1, A), revealing a similar
abundance of contaminating genomic DNA compared
to whole blood that has undergone a freeze–thaw cycle
(Fig. 1, B). cfDNA fragments typically display a charac-
teristic fragmentation profile with a prominent peak at
166 bp (5, 24). This peak was not observed, likely due
to the low mass of cfDNA in the blood spot and the
larger amounts of gDNA. To remove contaminating
gDNA fragments (>500 bp in length), we applied a
right-side size selection using AMPure beads. Running
another capillary electrophoresis after the bead-based
size selection revealed removal of the contaminating ge-
nomic DNA to varying degrees (Supplemental Fig. 1, B
and C). We generated a sequencing library from the
size-selected DNA using the ThruPLEX Tag-seq kit,
and obtained a total of 232 107 928 sequencing reads
(PE150; Illumina HiSeq4000; Fig. 1, A).
In our data, we achieved a unique sequencing depth
of 6 from sWGS following collapsing with a mini-
mum family size of 1 (17). Using a diversity estimator
[SPECIES (21)], we inferred that up to 10 unique
coverage are likely to be achieved from this blood-spot
library and may describe the total amount of cfDNA in
a blood spot after library preparation (see Methods).
Using dPCR, we quantified the DNA of extracted blood
spots after bead-based size selection. Using previously
described hLINE-1 primers we observed a high concen-
tration of human DNA (Supplemental Fig. 1, E) (9).
We then quantified blood-spot DNA using a less abun-
dant and copy-number neutral gene (14). Across 4 sam-
ples we obtained a median of 1322 amplifiable copies in
50 lL, equivalent to roughly 4.4 ng. This is more than
15-fold the expected concentration of 80 copies, which
we consider is likely due to varying amounts of remain-
ing contaminating genomic DNA (gDNA) after the
bead-based size selection (online Supplemental Fig. 1B
and C). Residual gDNA would lead to higher values
generated from PCR-based quantification of cfDNA,
though their effect on sequencing data would be limited
due to their low efficiency of library generation. These
findings suggest that the blood-spot material after size
selection still contains high molecular weight DNA,
Detection of ctDNA from Dried Blood Spots
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although not enough to inhibit library preparation.
Therefore, specific bead ratios for size selection are nec-
essary for effective clean-up of genomic DNA.
Sequencing data obtained from the blood spot were
analyzed for SCNAs using ichorCNA (Fig. 1, C) (2).
The alterations observed were consistent with those
identified in a matched plasma sample from the same
patient, isolated by standard plasma DNA-based meth-
ods (Fig. 1, C). The extent of SCNAs between the
2 samples was significantly correlated (Pearson r¼ 0.75,
P< 2.2  1016, Fig. 1, D) and similar to that found
in the initial tumor biopsy copy-number profile (Fig. 1,
C). The ichorCNA tumor fraction estimate for the
plasma sample was 0.11, compared to 0.07 for the
blood spot generated from the matched whole blood
sample following size selection. The similarity in
ctDNA levels between these samples despite the high
level of background in whole blood highlights the effi-
cacy of size selection for isolation of short cfDNA frag-
ments. We also identify a high correlation in log2 copy-
number profile between the plasma sample and the
metastatic tumor biopsy taken 6 days later (r¼ 0.90,
P¼ 2.2  1016). Discrepancies in the copy-number
profile between these 2 samples likely arise from sam-
pling error in the context of intratumor heterogeneity in
metastatic disease, consistent with previous literature
showing that subclonal mutations have lower ctDNA al-
lele fractions in plasma (25, 26).
Using sWGS, we show that the overall fragment-
size distribution of the human blood-spot cfDNA was
comparable to that of cfDNA derived from plasma (Fig.
1, E) (1, 5, 27). We then independently analyzed the
size distribution of mutant and wild-type reads, leverag-
ing mutation calls from exome sequencing of matched
tumor tissue in order to distinguish mutations from se-
quencing noise. This confirmed that tumor-derived
fragments were shorter in size compared to wild-type
fragments, with modal sizes of 150 and 170 bp, respec-
tively (Fig. 1, F), recapitulating size profiles derived
from plasma samples of patients with cancer (1, 5, 27).
Next, we assessed the extent of SCNAs in fresh
blood spots from whole blood of 2 patients with high-
grade serous ovarian cancer (see Methods). The first pa-
tient presented with Stage IIIC disease prior to the start
of fourth-line chemotherapy, while the second patient
had Stage IV disease and was stable on maintenance
therapy (Fig. 2). The sample from the patient who pre-
sented with a higher disease burden showed a corre-
spondingly greater magnitude of copy-number changes
compared to the other patient.
We next considered whether blood-spot analysis
may be used for longitudinal ctDNA monitoring in mu-
rine patient-derived xenograft (PDX) models. At pre-
sent, analysis of cfDNA is challenging in small rodents
as the volumes of blood required for most traditional
ctDNA analysis can only be obtained through terminal
bleeding. To assess the feasibility of dried blood-spot
analysis in animal models, we sampled 50 lL of whole
blood onto a dried blood-spot card from an orthotopi-
cally implanted ovarian tumor PDX model. DNA was
extracted and sequenced (see Methods). Following
alignment of sequencing reads, both human genome
(tumor-derived) and mouse genome (wild-type) reads
were observed, showing characteristic fragmentation
patterns of mutant and wild-type cfDNA (5) (Fig. 3, A).
SCNAs were observed in the human sequencing reads,
which mirrored the profile of both the original patient
ascites sample and the matched PDX tumor in the
mouse (Fig. 3, B). Finally, we quantified the amount of
human material in longitudinal blood spots (n¼ 3)
from a xenograft model using dPCR with primers
against hLINE-1 (9). The concentration of hLINE-1
tracked the tumor volume in the mouse over a course of
29 days (Fig. 3, C). Both of these applications demon-
strate that blood spots can be used to monitor disease
burden in animal models.
Discussion
In this study, we have demonstrated a new method to
detect ctDNA in drops/spots of whole blood from both
human and PDX samples. Our analysis mirrors observa-
tions previously made in cfDNA plasma analysis. This
approach relies on the use of size selection to remove ge-
nomic DNA, combined with ctDNA measurement
approaches such as sWGS that leverage signal from
across the entire genome. Because of the small amount
of material collected in this way, the analysis of any indi-
vidual locus would have limited sensitivity due to the
small number of genome copies of cfDNA that may be
obtained from a single blood spot (in the order of 80
copies). This method is therefore most appropriate for
analysis by highly multiplexed approaches leveraging sig-
nal from multiple loci. In this article, we demonstrated
analysis by low-depth WGS and by PCR-based analysis
of repetitive elements. Other approaches can include
analysis of multiple mutated loci (12) or epigenetic
analysis (28).
We analyzed a dried blood spot from a patient with
melanoma and observed a good correlation in the copy-
number profiles obtained from the blood spot and a
time-matched plasma and tumor sample. We obtained
similar cfDNA and ctDNA size profiles as observed
from standard plasma DNA-based methods. We further
analyzed fresh blood spots from patients with ovarian
cancer showing varying degrees of copy-number
changes, which reflected the patients’ disease burden.
Further work on larger cohorts with fresh finger prick
blood is warranted before progressing toward broader
use of blood spots for ctDNA monitoring. This work
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Fig. 3. ctDNA detection from a dried blood spot in a xenograft model. A) sWGS analysis of whole blood taken from a mouse xe-
nograft model of ovarian cancer (illustrated in the left panel). The fragment lengths of reads aligning to the human genome
(red, representing tumor ctDNA) were shorter than those aligning to the mouse genome (blue, representing non-tumor cfDNA).
B) Copy-number profiles were successfully generated from a dried blood spot from the mouse ovarian xenograft model
(Methods). The copy-number profiles of the original human ascites sample and the engrafted tumor are also shown. Segments
colored in blue, red, and green indicate regions of copy-number neutrality, gain, and loss, respectively. C) Human sequences
were quantified using a previously validated hLINE-1 assay (9) by dPCR. ctDNA levels are reported as hLINE-1 counts per lL elu-
ate for longitudinal blood-spot samples of a xenograft. Corresponding tumor volume measured in mm3 is also shown for the
same timeframe.
Detection of ctDNA from Dried Blood Spots
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should assess the amounts of ctDNA in blood spots and
compare the ctDNA fractions between blood spots and
matched plasma, assessing the extent to which they are
influenced by contaminating gDNA. Additionally, the
sensitivity limit for ctDNA analysis in blood spots
should be determined with both WGS and targeted
sequencing approaches. In future, the potential applica-
tion of personalized sequencing panels (12) to sequenc-
ing data could facilitate highly sensitive monitoring of
disease even from small volumes.
In addition, we have demonstrated the value of
this approach in animal models, allowing the detection of
SCNAs, human specific hLINE-1 sequences, and
the characteristic ctDNA fragmentation pattern from dried
blood spots of PDX models. In the monitoring of ctDNA
in small animal models, overcoming low circulating blood
volumes is a major challenge. Although tail vein blood
sampling in rodents has already been used for longitudinal
cancer monitoring from small blood samples, analysis was
limited to high copy-number markers such as hLINE-1
repeat sequences (9). Here, we highlight the possibility of
next generation sequencing of blood-spot cfDNA, en-
abling shallow and up to 6 WGS. Collecting samples
as dried blood spots would further simplify the logistical
burden associated with serial sampling of plasma by re-
moving the need for prompt centrifugation.
From a practical standpoint, the application of
dried blood spots could enable high-frequency ctDNA
monitoring of patients and animal models. Methods re-
lying on copy-number alterations have detected ctDNA
down to a mutant allele fraction of approximately 1–3%
(2, 5), limiting their application to patients with
advanced disease. However, even within the advanced
disease space, we envisage that this methodology may be
useful for patients for longitudinal cancer monitoring, as
an adjunct to conventional sampling from peripheral
blood tubes, and potentially enabling self-sampling for
cancer monitoring. Sampling and preanalytical processing
can be further simplified, potentially supporting new
study designs incorporating wider populations and more
frequent collection of smaller sample volumes. We hope
that detection of ctDNA from limited blood volumes will
enable novel approaches for cancer monitoring, such as
self-collection of samples at home followed by shipping
and centralized analysis, or novel point-of-care devices.
Although a qualitative and quantitative comparison of
ctDNA in both finger-prick and peripheral venous blood
samples was not performed in this study, such analyses
represent a logical next step for taking small-volume liq-
uid biopsy analyses into the clinic.
In addition to applications in oncology, sequencing
of cfDNA from dried blood spots may have utility
in other areas of medical diagnostics including noninva-
sive prenatal testing, monitoring transplant rejection,
and analysis of the cellular origins of cfDNA to identify
physiological or pathological changes such as identifica-
tion of tissue-specific cell death (28). Given that nucleic
acids can remain stable on card for years (29), Guthrie
cards might also be a useful medium for storage and
shipping of nonblood samples such as saliva. The ap-
proach we demonstrate here, whereby interfering geno-
mic DNA can be removed or excluded as part of
molecular analysis, may also prove useful for analysis
of biobanked or archived samples that may have been
collected by protocols that do not effectively remove
genomic DNA.
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